Table 6. Multivariate analysis of variables for prediction of SVR in GT2 and GT3.

	Genotype 2				Genotype 3
Baseline variables in patients with complete data available *	p	OR	95% CI for OR §		p	OR	95% CI for OR §
Age ≤45 years vs.>45 years					0.001	0.613	0.460	0.817
Cholesterol ≤130 vs.>130 mg/dl					0.001	1.768	1.277	2.446
γ-GT (U/l)> vs. ≤3 time ULN	0.011	0.341	0.148	0.785	0.030	0.585	0.361	0.950
APRI score <0.5. 0.5 - ≤1.5. 1.5 - ≤2	0.269				0.002	0.786	0.673	0.917
HCV-RNA ≤400,000 vs.>400,000 IU/ml					0.780
Psychiatric co-morbidity					0.165
Variables under treatment in patients with complete data *
RVR	0.000	3.770	1.930	7.362	0.001	1.63	1.212	2.203
Ribavirin starting dose (mg/kg body weight)	0.256				0.006	1.069	1.208	2.198

* For GT3 complete baseline data for multivariate analysis were available for 968 patients and in 341 patients with GT2; complete data under treatment were available for 787 patients with GT3 and for 180 patients with GT2.

^§OR  =  Odds Ratio; CI  =  Confidence interval.